Related Experiment Video

Updated: Aug 20, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Relationship between serum homocysteine, fibrinogen, lipoprotein-a level, and peripheral arterial disease: a

Hecheng Wang1, Pengpeng Wu1, Deying Jiang2

  • 1School of Life and Pharmaceutical Sciences, Dalian University of Technology, Dalian, China.

European Journal of Medical Research
|November 21, 2022
PubMed

Insights

Elevated serum homocysteine (Hcy), fibrinogen (FIB), and lipoprotein-a (LPa) are linked to increased peripheral artery disease (PAD) risk. Controlling Hcy levels may help reduce PAD incidence.

Area of Science:

  • Cardiovascular Medicine
  • Biomarkers
  • Epidemiology

Background:

  • The association between serum homocysteine (Hcy), fibrinogen (FIB), and lipoprotein-a (LPa) and peripheral artery disease (PAD) requires further clarification.
  • A comprehensive meta-analysis to establish dose-response relationships is lacking.

Purpose of the Study:

  • To investigate the dose-response relationship between serum Hcy, FIB, LPa levels and the risk of PAD.
  • To provide evidence for potential therapeutic targets in PAD prevention.

Main Methods:

  • A systematic literature search was conducted across PubMed, Embase, and Web of Science.
  • A robust error meta-regression method was employed to assess linear and non-linear dose-response relationships.
  • 68 articles involving 565,209 participants were included in the meta-analysis.

Main Results:

  • Serum Hcy, FIB, and LPa levels were significantly higher in PAD patients compared to controls.
  • Elevated Hcy, FIB, and LPa were associated with increased PAD risk (ORs: 1.47, 1.14, 1.76, respectively).
  • A U-shaped distribution was observed between Hcy levels and PAD risk; each 1 μmol/L increase in Hcy correlated with a 7% PAD risk increase.

Conclusions:

  • Elevated serum Hcy, FIB, and LPa levels are associated with an increased risk of PAD.
  • The risk of PAD escalates with increasing serum exposure levels within a defined range.
  • Managing Hcy levels presents a potential strategy to mitigate the growing epidemic of PAD.
Abstract

Keywords:
Dose–response meta-analysisFibrinogenHomocysteineLipoprotein(a)Peripheral arterial disease

More Related Videos

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

27.4K
Assessing Endothelial Vasodilator Function with the Endo-PAT 200007:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

43.8K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
139
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
219
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
22
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
35
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
24